Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Account Payables
Amounts the company owes suppliers for goods and services received.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 125.8% from a year ago
Account payables stood at $6.19M at the end of Q1 FY2026, up 125.8% from a year earlier and up 12.2% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.
Context
- Account payables amounted to 1.1% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +125.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 5.52M USD
- Year-over-year change
- +22.3%
- 3-year CAGR
- +2.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.52M | +22.3% |
| FY2024 | 2024-12-31 | 4.51M | +41.5% |
| FY2023 | 2023-12-31 | 3.19M | -38.0% |
| FY2022 | 2022-12-31 | 5.14M | — |
Account Payables vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 account payables of $6.19M is the highest of the 6 companies compared; the peer median is $2.47M.
- Its year-over-year change of +125.8% is the 3rd highest of 6, against a peer median of -26.2%.
- Account payables amounts to 1.1% of total assets for BCAX, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $6.19M | +125.8% | +2.4% | 1.1% |
| Mar 2026 | $4.29M | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $2.51M | -26.2% | -31.9% | 0.6% | |
| Mar 2026 | $2.47M | +146.3% | +39.3% | 4.2% | |
| Mar 2026 | $1.19M | +702.7% | +117.6% | 0.6% | |
| Mar 2026 | $906K | -42.5% | -22.3% | 0.4% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $2.47M | -26.2% | -0.8% | 0.6% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.